NICE gives green light for MSD’s Keytruda
The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study
Read More
Tag: MSD
Astex reveals partnership with MSD
The partnership will establish small molecule candidates with a view to treating cancer
Read More
MSD’s HCV report calls for key elimination boosts
The advice includes a national rollout of the HCV GP champion programme and further testing
Read More
MSD’s Keytruda given go-ahead by SMC
Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer
Read More
AstraZeneca and MSD’s Lynparza gets green light
Combination therapy treat patients with metastatic castration-resistant prostate cancer
Read More
New laboratory space for MSD at The Francis Crick Institute
Move represents the latest phase of preparation for the opening of MSD’s new UK Discovery Centre
Read More
Tilt collaborates with MSD on immunotherapy clinical trial
The study will focus on checkpoint inhibitor refractory non-small cell lung cancer
Read More
MSD’s pembrolizumab therapy gets NICE approval
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning
Read More
Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
NICE approval is for first-line treatment of intermediate and advanced renal cell carcinoma
Read More
Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial
The companies will evaluate Trodelvy plus Keytruda for the first-line treatment of certain triple-negative breast cancer patients
Read More
EC approves Keytruda regimen for triple-negative breast cancer
Approval covers patients with locally recurrent or metastatic TNBC
Read More
MSD’s pneumococcal vaccine hits ‘key endpoints’ in Phase III
Phase III trial evaluated use in infants 42-90 days old
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
